No Data
No Data
Cofco Biotechnology: China National Chemical Corporation biotechnology limited company's performance forecast for the first half of 2024.
Cofco Biotechnology (000930.SZ): Expected profit of 530-680 million yuan in the first half of the year, turning losses into gains year-on-year.
On July 11th, Gelunhui reported that Cofco Biotech (000930.SZ) announced its performance forecast for the first half of 2024. According to preliminary calculations by the financial department, it is expected to achieve a net income attributable to shareholders of the listed company of 53 million to 68 million yuan, an increase of 116%-120% compared to the same period last year; net income after deducting non-recurring gains and losses is expected to be 16 million to 20 million yuan, an increase of 104%-106% over the same period last year. Basic earnings per share are 0.0291 yuan/share to 0.0371 yuan/share. In the first half of 2024, the company adopted a "slow harvesting and fast selling" strategy.
Cofco Biotechnology (000930.SZ): Appointed Chen Shaohui as Vice General Manager.
Cofco Biotechnology (000930.SZ) announced on July 3 that the company held the fourth interim meeting of the eighth board of directors on July 1, 2024. It approved the proposal of appointing Chen Shaohui as the deputy general manager of the company as nominated by Zhang Deguo, the general manager of the company, and approved by the nomination committee of the board of directors of the company due to the needs of the company's work. The term of office is from the date of the approval of this board of directors to the expiration of the eighth board of directors.
Selected announcements from geloncize: shanghai microport endovascular medtech(group)co.,ltd. expects net income to increase by 40% to 50% year-on-year in the first half of the year; cofco biotechnology plans to invest 185 million yuan to expand its Cheng
Investment project: Cofco Biotechnology (000930.SZ): plans to invest 185 million yuan to expand Chengdu company's annual production of 150,000 tons of starch sugar projects. Cofco Biotechnology (000930.SZ) announced that in order to improve the industrial layout of starch sugar business, enhance market share, and improve market competitiveness, the company plans to invest in expanding the COFCO Biochemical (Chengdu) Co., Ltd.'s 150,000 tons/year starch sugar project. The total investment is approximately 185,261.3 million yuan (the final total investment of the project is subject to actual investment). The construction period is 18 months from the date of project approval to successful commissioning. Contract Award: Hongrun Construction Group (00206
COFCO Biotechnology Co., Ltd.'s (SZSE:000930) Share Price Is Matching Sentiment Around Its Revenues
With a price-to-sales (or "P/S") ratio of 0.5x COFCO Biotechnology Co., Ltd. (SZSE:000930) may be sending bullish signals at the moment, given that almost half of all the Chemicals companies in China
COFCO, a Henricksen Company, Opens New Experience Center and Rebrands to Henricksen
WASHINGTON, May 1, 2024 /PRNewswire/ -- Henricksen is pleased to announce the opening of their Washington DC Experience Center located on the 5th floor of 1725 I Street and the rebrand of COFCO, a He
No Data